- Report
- March 2024
- 196 Pages
Global
From €3277EUR$3,374USD£2,827GBP
€3641EUR$3,749USD£3,141GBP
- Report
- February 2024
- 250 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- April 2024
- 164 Pages
Global
From €5293EUR$5,450USD£4,566GBP
- Clinical Trials
- April 2024
- 100 Pages
Global
From €2914EUR$3,000USD£2,514GBP
- Report
- January 2024
- 200 Pages
Global
From €4031EUR$4,150USD£3,477GBP
- Report
- February 2024
- 112 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1457EUR$1,500USD£1,257GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Report
- June 2023
- 200 Pages
Global
From €7284EUR$7,500USD£6,284GBP
- Report
- March 2024
- 115 Pages
Global
From €4371EUR$4,500USD£3,770GBP
- Report
- September 2023
- 180 Pages
Global
From €5342EUR$5,500USD£4,608GBP
- Report
- April 2024
- 898 Pages
Global
From €5439EUR$5,600USD£4,692GBP
- Report
- November 2023
- 143 Pages
Global
From €2427EUR$2,499USD£2,094GBP
- Report
- December 2021
- 220 Pages
Global
From €2331EUR$2,400USD£2,011GBP
- Report
- February 2021
- 120 Pages
Global
From €5779EUR$5,950USD£4,985GBP
- Report
- April 2020
Global
From €3885EUR$4,000USD£3,351GBP
- Report
- May 2021
- 138 Pages
Asia Pacific
From €2040EUR$2,100USD£1,760GBP
€2914EUR$3,000USD£2,514GBP
The Multiple Sclerosis (MS) Drug market is a subset of the Central Nervous System (CNS) Drugs market. MS is a chronic, progressive neurological disorder that affects the central nervous system, causing a wide range of physical and mental symptoms. MS drugs are used to reduce the frequency and severity of MS relapses, slow the progression of the disease, and improve the quality of life of those affected.
MS drugs are typically divided into two categories: disease-modifying therapies (DMTs) and symptomatic therapies. DMTs are used to slow the progression of the disease, while symptomatic therapies are used to manage the symptoms of MS. Common DMTs include interferon beta, glatiramer acetate, fingolimod, and natalizumab. Common symptomatic therapies include muscle relaxants, antispasmodics, and antidepressants.
The MS Drug market is highly competitive, with a number of major pharmaceutical companies competing for market share. Some of the major players in the market include Biogen, Novartis, Merck, Sanofi, and Teva Pharmaceuticals. Show Less Read more